度洛西汀改善肩袖修复术后焦虑抑郁患者早期临床结局
这项随机对照试验纳入63例关节镜下肩袖修复患者,按HADS评分及是否口服度洛西汀分为三组。结果显示,度洛西汀组术后3个月内活动度、功能评分、焦虑评分和疼痛评分均优于未用药的心理困扰组,但16%患者出现恶心呕吐。
要点
- 度洛西汀可改善焦虑抑郁患者肩袖修复术后3个月内的活动度与功能。
- 度洛西汀组术后3个月内阿片类药物消耗少于未用药的心理困扰组。
- 16%使用度洛西汀的患者出现恶心呕吐,但无严重不良事件。
核心结论
- 对HADS筛查存在焦虑和/或抑郁的关节镜下肩袖修复患者,度洛西汀可改善术后前3个月的焦虑、活动度、ASES和SST评分。
研究设计与样本
- 随机对照临床试验,证据等级2,共纳入63例接受关节镜下肩袖修复的慢性肩袖撕裂患者。
主要发现
- 术后3个月内,B组活动度、ASES、SST、焦虑评分和疼痛评分均优于C组(均调整P<.05)。
- A组与B组在上述指标上差异无统计学意义(均调整P>.05)。
- 后续随访中三组功能结局和再撕裂率无差异。
- B组16%(4/25)患者出现恶心呕吐,经止吐干预后症状完全缓解但退出研究。
关键数值与推荐
- 分组标准:A组焦虑<8且抑郁<8(n=20);B组焦虑≥8和/或抑郁≥8且口服度洛西汀(n=21);C组焦虑≥8和/或抑郁≥8且未用度洛西汀(n=22)。
- 度洛西汀用法:手术当晚开始口服,前2周30 mg/d,之后增至60 mg/d共12周。
- 主要结局为术后3个月主动前屈活动度。
临床怎么用
- 对拟行关节镜下肩袖修复且HADS提示焦虑和/或抑郁的患者,可考虑围手术期使用度洛西汀以改善早期功能恢复。
- 使用度洛西汀时需监测恶心呕吐等不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anxiety and depression are known risk factors for poor prognosis after arthroscopic rotator cuff repair (ARCR). However, studies that examine relief of postoperative psychological distress in patients with anxiety and/or depression remain limited. PURPOSE: To evaluate the effect of duloxetine on the clinical outcomes of ARCR for chronic rotator cuff tears in patients with anxiety and/or depression. STUDY DESIGN: Randomized controlled clinical trial; Level of evidence, 2. METHOD: A total of 63 patients undergoing ARCR were enrolled and categorized into 3 groups based on Hospital Anxiety and Depression Scale (HADS) scores and the use of oral duloxetine: group A (anxiety <8 and depression <8, healthy psychological status; n = 20); group B (anxiety ≥8 and/or depression ≥8, psychological distress receiving duloxetine administration; n = 21); and group C (anxiety ≥8 and/or depression ≥8, psychological distress receiving no duloxetine treatment; n = 22). Duloxetine was administered orally from the evening of the surgery. The dosage was 30 mg/d for the first 2 weeks. After the adaptation period, the dosage was increased to 60 mg/d for 12 weeks. Primary outcome was active forward flexion at postoperative 3 months. Other functional outcomes, structural outcomes, analgesic consumption, and duloxetine-related side effects were assessed at postoperative 3, 6, and 12 months and annually thereafter. RESULTS: No severe adverse events related to duloxetine were observed. However, 16% (4/25) of patients in group B experienced nausea and vomiting after duloxetine administration. Although symptoms resolved completely after antiemetic intervention, the patients withdrew from the study due to the drug-related adverse event. In the first 3 months after surgery, group B showed better range of motion (ROM), better functional outcomes (American Shoulder and Elbow Surgeons Standardized Assessment Form [ASES] and Simple Shoulder Test [SST]), better anxiety scores, better pain scores, and less opioid consumption than did group C (all adjusted P < .05). These differences were not observed between groups A and B (all adjusted P > .05). Functional outcomes and retear rates did not differ among the 3 groups at later follow-up. CONCLUSION: Administration of duloxetine to ARCR patients with anxiety and/or depressive distress screened using HADS not only improved anxiety and distress but also enhanced active ROM, ASES, and SST in the first 3 months postoperatively, although 16% of patients experienced nausea and vomiting.
引用
- Han SC, Han J, Min YK, et al. Duloxetine Improves Early Clinical Outcomes Including Range of Motion, Functional Scores, Pain, and Psychological Distress After Arthroscopic Rotator Cuff Repair in Patients With Anxiety or Depression: Prospective Randomized Controlled Trial. Am J Sports Med. 2026. PMID: 41934361. doi:10.1177/03635465261430918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。